Open AccessProtein modification by thiolactone homocysteine chemistry: a multifunctionalized human serum albumin theranostic
Author(s) -
Tatyana V. Popova,
Olesya A. Krumkacheva,
Anna S. Burmakova,
Anna Spitsyna,
Olga D. Zakharova,
Vladimir A. Lisitskiy,
Igor A. Kirilyuk,
Vladimir N. Silnikov,
Michael K. Bowman,
Elena G. Bagryanskaya,
Tatyana S. Godovikova
Publication year - 2020
Publication title -
rsc medicinal chemistry
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.754
H-Index - 55
ISSN - 2632-8682
DOI - 10.1039/c9md00516a
Subject(s) - chemistry , conjugate , albumin , serum albumin , tamoxifen , human serum albumin , biochemistry , combinatorial chemistry , cancer , breast cancer , medicine , mathematical analysis , mathematics
As the most abundant protein with a variety of physiological functions, albumin has been used extensively for the delivery of therapeutic molecules. Thiolactone chemistry provides a powerful tool to prepare spin-labeled albumin-based multimodal imaging probes and therapeutic agents. We report the synthesis of a tamoxifen homocysteine thiolactone derivative and its use in thiol-'click' chemistry to prepare multi-functionalized serum albumin. The released sulfhydryl group of the homocysteine functional handle was labeled with a nitroxide reagent to prepare a spin-labeled albumin-tamoxifen conjugate confirmed by MALDI-TOF-MS, EPR spectroscopy, UV-vis and fluorescent emission spectra. This is the basis for a novel multimodal tamoxifen-albumin theranostic with a significant (dose-dependent) inhibitory effect on the proliferation of malignant cells. The response of human glioblastoma multiforme T98G cells and breast cancer MCF-7 cells to tamoxifen and its albumin conjugates was different in tumor cells with different expression level of ERα in our experiments. These results provide further impetus to develop a serum protein for delivery of tamoxifen to cancer cells.